Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21079
- CHU de DIJON
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who have provided oral consent
- Patients older than 18
- Patients with type 1 or 2 diabetes
- Patients who can be followed-up in the context of consultations for diabetic foot at the endocrinology, diabetology and metabolic diseases unit of Dijon CHU.
- Lesion situated on a toe or on the plantar or dorsal side of the foot
- Lesion that has evolved for 1 to 24 months
Exclusion Criteria:
- Adult under guardianship
- Patient without national health insurance
- Pregnant or breast-feeding women
- Patients with progressive cancer
- Patients with terminal renal insufficiency on dialysis
- Patient with severe respiratory insufficiency
- Patients with terminal heart failure
- Patients with severe liver failure
- Patients with immunodepriession (treatement with immunosuppressants, long-term corticotherapy, diseases leading to immunodepression)
- Patients with nephrotic syndrome (hypoalbuminemia)
- Patientswith a chronic inflammatory syndrome
- Alcohol consumption greater than 4 glasses per day
- Systemic infection uncontrolled by antibiotics
- Infected lesion with systemic repercussions
- Charcot foot
- Patients taking part or who have planned to take part in another clinical trial
- Severe disease affecting survival in the short term
- Lesion on an amputation
- Lesion of the ankle or leg
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Diabetic patients with a lesion on the foot
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of healed lesions
Time Frame: After 24 weeks of follow-up
|
After 24 weeks of follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of malnourished patients according to HAS 2003 and 2007 criteria
Time Frame: At inclusion
|
At inclusion
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of healed lesions during the follow-up
Time Frame: At 2, 4, 8, 12, 16 and 20 weeks
|
At 2, 4, 8, 12, 16 and 20 weeks
|
|
Number of malnourished patients at 12 and 24 weeks
Time Frame: At 12 and 24 weeks
|
At 12 and 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BOUILLET 2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Type 1 or 2 Diabetes
-
NCT02080741TerminatedPatients With Type 1 or Type 2 Diabetes | Patients With a Type A or B Behaviour Profile
-
NCT06674161Not yet recruitingCardiovascular Diseases | Cardiovascular Diseases Risk | Mortality of Patients with CVD | Mortality of Patients with CVD and T2DM | Mortality of Patients with T2DM | Mortality of Patients with Neither | Morbidity of CVD
-
NCT06007014Not yet recruitingEfficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients | Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect | 128 Patients Were Randomly Assigned 1:1 | Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day Group | Metformin and Insulin Glargine Combined With Placebo Group | InvestigatorInitiate Trial | Changes in HbA1C From Baseline at 18 Weeks of Treatment
-
NCT03727854CompletedPatients With Type 2 Diabetes
-
NCT00703482Completed
-
NCT05893797CompletedType 1 Diabetes | Type 2 Diabetes | Type 2 Diabetes Treated With Insulin
-
NCT01974674UnknownPatients With Type 1 Diabetes
-
NCT05697484Not yet recruitingDiabetic Pediatric Patients With Type 1 Diabetes
-
NCT06871761CompletedAdult Patients With Type 2 Diabetes
-
NCT07463209Not yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)
Clinical Trials on biological examination at consultations at 3 and 6 months
-
NCT02065297CompletedInfectious Disease | Solid Tumor | Hemopathy | Horton's Disease | Neoplasia
-
NCT04538027Completed
-
NCT01089829UnknownChronic Kidney Disease
-
NCT07184463RecruitingThoracic Surgery | Video-assisted Thoracic Surgery | Robotic-assisted Thoracic Surgery
-
NCT07530679Not yet recruiting
-
NCT03117868Completed
-
NCT02850497CompletedRecurrent Angina After Coronary Stent Placement